Fox Corp Class B vs Sana Biotechnology Inc — how do they compare? Fox Corp Class B trades at $55.3 (market cap $24.58B), while Sana Biotechnology Inc trades at $3.81 (market cap $1.13B). The key difference: Fox Corp Class B is far larger — about 21.8× Sana Biotechnology Inc's market cap, and Fox Corp Class B pays a 1.05% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| FOX | SANA | |
|---|---|---|
Market Cap | $24.58B | $1.13B |
Sector | Media | Health |
52-Week High | $67.76 | $5.92 |
52-Week Low | $44.39 | $2.68 |
Enterprise Value | $27.94B | $1.05B |
Dividend Yield | 1.05% | — |
Signals from Pluang's Aura AI — not financial advice
FOX trades at $56.33, down 1.23% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent earnings beats and strong 2025 results, including $16.3B revenue and $2.26B net income, support a P/E of 14.41. Positive news includes Tubi's partnership with Gracenote for CTV advertising growth (PRNewswire, Aug 12, 2026).
The outlook is positive with robust ad momentum and digital expansion, though risks include cyclical advertising exposure and high RSI suggesting near-term pullback potential. Analyst consensus leans neutral with 42.86% buy ratings, indicating cautious optimism for long-term holders amid competitive media pressures.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Trailing returns across standard periods
Latest headlines on both assets
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →